Cancer Cell, Volume *12*

Supplemental Data

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

Sumin Kang, Shaozhong Dong, Ting-Lei Gu, Ailan Guo, Michael S. Cohen, Sagar Lonial, Hanna Jean Khoury, Doriano Fabbro, D. Gary Gilliland, P. Leif Bergsagel, Jack Taunton, Roberto D. Polakiewicz, and Jing Chen

Figure S1

U0126 treatment inhibits FGFR3-dependent activation of RSK2. Ba/F3 cells stably expressing FGFR3 TDII and myc-tagged RSK2 WT or ΔC20 mutant were cultured in the presence of aFGF with withdrawal of IL-3 and serum for 4 hours. Cells were treated with U0126 (10μM) for 90 min prior to harvest of cell lysates. *Upper:* Immunocomplexes of myc-tagged RSK2 variants were isolated and incubated with equal amount of S6-peptide and [γ-^{32}P] ATP. The phosphorylation of S6 peptide was normalized to readings from reactions using myc-immunocomplexes from cells stably expressing FGFR3 TDII alone in the absence of U0126 (0.0), and cells co-expressing TDII and myc-RSK2 WT in the absence of U0126 (1.0). The data were presented as mean+/-SD (n=3). *Lower:* Parallel immunoprecipitation and Western blotting results confirmed equal amounts of myc-RSK2 proteins in each kinase reaction.